These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 8648603)

  • 1. Synthesis and cyclic GMP phosphodiesterase inhibitory activity of a series of 6-phenylpyrazolo[3,4-d]pyrimidones.
    Dumaître B; Dodic N
    J Med Chem; 1996 Apr; 39(8):1635-44. PubMed ID: 8648603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability.
    Allerton CM; Barber CG; Beaumont KC; Brown DG; Cole SM; Ellis D; Lane CA; Maw GN; Mount NM; Rawson DJ; Robinson CM; Street SD; Summerhill NW
    J Med Chem; 2006 Jun; 49(12):3581-94. PubMed ID: 16759100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors.
    Xia Y; Chackalamannil S; Czarniecki M; Tsai H; Vaccaro H; Cleven R; Cook J; Fawzi A; Watkins R; Zhang H
    J Med Chem; 1997 Dec; 40(26):4372-7. PubMed ID: 9435906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
    Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
    J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent and selective xanthine-based inhibitors of phosphodiesterase 5.
    Arnold NJ; Arnold R; Beer D; Bhalay G; Collingwood SP; Craig S; Devereux N; Dodds M; Dunstan AR; Fairhurst RA; Farr D; Fullerton JD; Glen A; Gomez S; Haberthuer S; Hatto JD; Howes C; Jones D; Keller TH; Leuenberger B; Moser HE; Muller I; Naef R; Nicklin PA; Sandham DA; Turner KL; Tweed MF; Watson SJ; Zurini M
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2376-9. PubMed ID: 17337182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues.
    Daugan A; Grondin P; Ruault C; Le Monnier de Gouville AC; Coste H; Linget JM; Kirilovsky J; Hyafil F; Labaudinière R
    J Med Chem; 2003 Oct; 46(21):4533-42. PubMed ID: 14521415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity.
    Ahn HS; Bercovici A; Boykow G; Bronnenkant A; Chackalamannil S; Chow J; Cleven R; Cook J; Czarniecki M; Domalski C; Fawzi A; Green M; Gündes A; Ho G; Laudicina M; Lindo N; Ma K; Manna M; McKittrick B; Mirzai B; Nechuta T; Neustadt B; Puchalski C; Pula K; Zhang H
    J Med Chem; 1997 Jul; 40(14):2196-210. PubMed ID: 9216839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substituted pyrazolopyridopyridazines as orally bioavailable potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction.
    Yu G; Mason H; Wu X; Wang J; Chong S; Beyer B; Henwood A; Pongrac R; Seliger L; He B; Normandin D; Ferrer P; Zhang R; Adam L; Humphrey WG; Krupinski J; Macor JE
    J Med Chem; 2003 Feb; 46(4):457-60. PubMed ID: 12570368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5.
    Wang G; Liu Z; Chen T; Wang Z; Yang H; Zheng M; Ren J; Tian G; Yang X; Li L; Li J; Suo J; Zhang R; Jiang X; Terrett NK; Shen J; Xu Y; Jiang H
    J Med Chem; 2012 Dec; 55(23):10540-50. PubMed ID: 23137303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on griseolic acid derivatives. I. Synthesis of substituted derivatives of griseolic acid at the N1, C6, C2' or C7' position and their biological activities.
    Kaneko M; Murofushi Y; Kimura M; Yamazaki M; Iijima Y
    Nucleic Acids Symp Ser; 1985; (16):89-92. PubMed ID: 3003711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDE5 inhibitors: An original access to novel potent arylated analogues of tadalafil.
    Beghyn T; Hounsou C; Deprez BP
    Bioorg Med Chem Lett; 2007 Feb; 17(3):789-92. PubMed ID: 17107795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues.
    Daugan A; Grondin P; Ruault C; Le Monnier de Gouville AC; Coste H; Kirilovsky J; Hyafil F; Labaudinière R
    J Med Chem; 2003 Oct; 46(21):4525-32. PubMed ID: 14521414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
    Bi Y; Stoy P; Adam L; He B; Krupinski J; Normandin D; Pongrac R; Seliger L; Watson A; Macor JE
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1577-80. PubMed ID: 15006407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and thromboxane synthesis inhibitory activities.
    Lee SJ; Konishi Y; Yu DT; Miskowski TA; Riviello CM; Macina OT; Frierson MR; Kondo K; Sugitani M; Sircar JC
    J Med Chem; 1995 Sep; 38(18):3547-57. PubMed ID: 7658441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity.
    Takase Y; Saeki T; Watanabe N; Adachi H; Souda S; Saito I
    J Med Chem; 1994 Jun; 37(13):2106-11. PubMed ID: 8027992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and SAR of tetracyclic pyrroloquinolones as phosphodiesterase 5 inhibitors.
    Jiang W; Alford VC; Qiu Y; Bhattacharjee S; John TM; Haynes-Johnson D; Kraft PJ; Lundeen SG; Sui Z
    Bioorg Med Chem; 2004 Mar; 12(6):1505-15. PubMed ID: 15018924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New 2-aryl-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-4-one derivatives as diuretics.
    Monge A; Martinez-Merino V; Simon MA; Sanmartin C
    Arzneimittelforschung; 1993 Dec; 43(12):1322-6. PubMed ID: 8141821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5).
    Corbin JD; Beasley A; Blount MA; Francis SH
    Neurochem Int; 2004 Nov; 45(6):859-63. PubMed ID: 15312980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3D-QSAR studies on sildenafil analogues, selective phosphodiesterase 5 inhibitors.
    Yoo J; Thai KM; Kim DK; Lee JY; Park HJ
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4271-4. PubMed ID: 17553682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemodynamic effects of phosphodiesterase 5 and angiotensin-converting enzyme inhibition alone or in combination in conscious SHR.
    Gardiner SM; March JE; Kemp PA; Ballard SA; Hawkeswood E; Hughes B; Bennett T
    J Pharmacol Exp Ther; 2005 Jan; 312(1):265-71. PubMed ID: 15452190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.